ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2022
Extensively drug-resistant (XDR)
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open-label randomized cross-over study in healthy subjects.Clinical and translational science · 2023Trial
- Rapid detection of ceftriaxone-resistantMicrobiology spectrum · 2026Article
- Limitations of Global Surveillance for Neisseria gonorrhoeae Antimicrobial Resistance.Emerging infectious diseases · 2026Review
- Extensively drug-resistant (XDR)Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- [Superbugs Neisseria gonorrhoeae und Mycoplasma genitalium : Therapeutic challenges driven by antimicrobial resistance].Dermatologie (Heidelberg, Germany) · 2026Review
- Gonorrhea Management in High-, Limited- and No-Resource Settings: Implications in the Context of Antimicrobial Resistance.International journal of dermatology · 2026Review
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24.The Journal of antimicrobial chemotherapy · 2026Article
- Article
- Detection of non-travel-associated, ceftriaxone non-susceptibleCanada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- Investigation of ceftriaxone-resistantSexually transmitted infections · 2025Article
- Estimating the undetected burden and the likelihood of strain persistence of drug-resistant Neisseria gonorrhoeae.American journal of epidemiology · 2025Article
- The World Health Organization (WHO) Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) reports continuously high levels of ceftriaxone resistance across Viet Nam, 2024.The Lancet regional health. Western Pacific · 2025Article
- Autochthonous transmission of extensively drug-resistantEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- WHO global gonococcal antimicrobial surveillance programmes, 2019-22: a retrospective observational study.The Lancet. Microbe · 2025Observational
- CommensalAnnual review of microbiology · 2025Review
- Antimicrobial resistance inThe Lancet regional health. Western Pacific · 2025Article
- Extensively Drug-Resistant Neisseria gonorrhoeae Strain, Canada.Emerging infectious diseases · 2025Article
- Antimicrobial resistance inThe Lancet regional health. Europe · 2025Article
- New Trends in Sexually Transmitted Infections Among Adolescents and Young People: Epidemiology, Clinical and Diagnostic Management.Microorganisms · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe a gonorrhoea case with ceftriaxone plus high-level azithromycin resistance. In April 2022, an Austrian heterosexual male was diagnosed with gonorrhoea after sexual intercourse with a female sex worker in Cambodia. Recommended treatment with ceftriaxone (1 g) plus azithromycin (1.5 g) possibly failed. Worryingly, this is the second strain in an Asian
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.